Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 2/20 | 0.33 |
| ▸ | MGMT | P16455 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13843313 | 0.83 | ADORA2A (0.37) | ADORA2AADORA3ADORA2BHSPA5HIF1A | |
| SCHEMBL13847083 | 0.83 | ADORA2A (0.37) | ADORA2AADORA3ADORA2BHSPA5HIF1A | |
| SCHEMBL13847082 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA2BHSPA5HIF1A | |
| SCHEMBL13843348 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA2BHSPA5HIF1A | |
| SCHEMBL3993915 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA2BHSPA5HIF1A | |
| SCHEMBL13843356 | 0.79 | MTAP (0.43) | — | |
| SCHEMBL13847228 | 0.79 | MTAP (0.43) | — | |
| SCHEMBL13843333 | 0.77 | CYP1A2 (0.30) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL13847197 | 0.68 | ADORA2A (0.35) | ADORA2AADORA3HIF1A | |
| SCHEMBL13847181 | 0.67 | ADORA2A (0.34) | ADORA2AADORA3HSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534767-B2 | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | NSUN2, PNP, RNGTT | ADORA2A 106/4885ADORA3 95/4885ADORA2B 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.